J Korean Ophthalmol Soc > Volume 61(2); 2020 > Article
Journal of the Korean Ophthalmological Society 2020;61(2):183-189.
DOI: https://doi.org/10.3341/jkos.2020.61.2.183    Published online February 15, 2020.
Bromfenac as Adjunctive Treatment with Intravitreal Bevacizumab in Branch Retinal Vein Occlusion of Macular Edema.
Jong Myoung Yun, Young Wook Cho, Jong Won Moon
Department of Ophthalmology, Daegu Fatima Hospital, Daegu, Korea. anantos@naver.com
황반부종이 동반된 망막분지정맥폐쇄에서 베바시주맙 유리체내주사의 보조치료로써 브롬페낙의 효과
윤종명 · 조영욱 · 문종원
대구파티마병원 안과
Correspondence:  Jong Won Moon,
Email: anantos@naver.com
Received: 20 June 2019   • Revised: 14 October 2019   • Accepted: 17 January 2020
Abstract
PURPOSE
To evaluate the effectiveness of 0.1% topical bromfenac as an adjunctive treatment with intravitreal bevacizumab (IVB) injection for branch retinal vein occlusion (BRVO) patients. METHODS: We retrospectively evaluated 68 eyes of 68 patients with macular edema (ME) secondary to BRVO who were treated with IVB injection and followed up for at least 12 months. Of the 68 eyes, 38 were treated with IVB combined with 0.1% topical bromfenac and 30 were treated with IVB alone. IVB reinjection was performed in cases of recurrence. The primary outcome measurement was the number of IVB injections. Changes in the best-corrected visual acuity (BCVA) and central foveal thickness (CFT) during the 12-month follow-up were compared. RESULTS: There was no significant difference in the BCVA or CFT between the two groups at the initial and final examinations. However, the number of IVB injections was significantly lower in the 0.1% bromfenac-treated eyes (p < 0.01) than in the control eyes (4.1 ± 0.7 vs. 5.0 ± 0.6 times). CONCLUSIONS: Compared to IVB monotherapy, topical bromfenac as an adjunctive treatment with IVB injection of eyes with ME secondary to BRVO did not affect visual outcomes, but it reduced the number of IVB injections.
Key Words: Bevacizumab;Branch retinal vein occlusion;Macular edema;Nonsteroidal anti-inflammatory drug (NSAIDs)


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next